ReviewPulse (Basel, Switzerland)2021
Sickle Cell Disease-Induced Pulmonary Hypertension: A Review of Pathophysiology, Management, and Current Literature.
Review in Pulse (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Quantification of chronic vascular remodeling in sickle cell disease.European radiology · 2026Article
- The Role of Platelet-to-Neutrophil Ratio as a Biomarker for Pulmonary Hypertension in Sickle Cell Disease Patients: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Growth differentiation factor-15 as a non-invasive biomarker of liver fibrosis in sickle cell disease.International journal of hematology · 2025Article
- Systematic Review of Extracorporeal Membrane Oxygenation in Adult Sickle Cell Disease.Journal of clinical medicine · 2025Review
- Early detection of pulmonary vasculopathy in children with sickle cell disease by new echocardiography-based blood speckle technology.BMC pediatrics · 2025Article
- Pulmonary Hypertension in the Field of Hematological and Oncological Diseases.Respiration; international review of thoracic diseases · 2025Review
- Screening for pulmonary hypertension in pregnant women with sickle cell disease in sub-Saharan Africa.AJOG global reports · 2024Article
- Electrocardiographic findings in patients with sickle cell disease: A protocol for systematic review and meta-analysis.Health science reports · 2024Article
- Prevalence of Pulmonary Hypertension among Sudanese Patients with Sickle Cell Disease.The open respiratory medicine journal · 2024Article
- Cardiovascular Consequences of Sickle Cell Disease.Journal of blood medicine · 2024Article
- Clinical-radiological-pathological correlation in pulmonary hypertension with unclear and/or multifactorial mechanisms.European respiratory review : an official journal of the European Respiratory Society · 2023Article
- Article
- Sickle Cell Disease (SCD) Leading to Pulmonary Arterial Hypertension (PAH) and Cholelithiasis (CL).Cureus · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease is an inherited hemoglobinopathy leading to the synthesis of hemoglobin S. Hemoglobin S results in the formation of abnormal sickle-shaped erythrocytes that lead to hematologic abnormalities such as hemolytic anemia and increased risks of thrombosis. Another particular problem encountered with the disease is pulmonary hypertension. The objective of this narrative review is to discuss the prevalence, pathophysiology mechanisms, diagnostic techniques, treatment options, and prognostic indicators in the setting of sickle cell disease with pulmonary hypertension. Additionally, the review also highlights other advancements that are being investigated. Considering the significant morbidity, mortality, and prevalence of pulmonary hypertension in patients with sickle cell disease, it is important to account for the aforementioned domains in the future guidelines to provide optimal and individualized care to the high-risk individuals as well as reduce the progression of disease, morbidity, and mortality rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.